---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-033867"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2026-03-24T23:59:59+00:00"
generated_at: "2026-05-15T09:10:08.763740+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q4 revenue $7.3M, down 16%; FY2025 revenue $33M; guides FY2026 $30-32M

## Summary
- Q4 2025 total revenue $7.3M (-16% YoY); Core revenue $6.8M (-22% YoY). Net loss $9.6M.
- FY2025 total revenue $33.0M (-15% YoY); Core revenue $29.6M (-9% YoY). Net loss $44.6M.
- Cash and investments $155.6M at Dec 31, 2025, vs $190.3M a year earlier.
- FY2026 guidance: total revenue $30-32M ($25-27M core, $5M SPL); expects cash ≥$136M.
- Ended 2025 with 32 SPLs, 13 clinical programs in clinic, and one commercial program.

## SEC filing metadata
- accession: 0001104659-26-033867
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2026-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/mxct-20260324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-033867
- JSON: https://secwatch.observer/filing/0001104659-26-033867.json
- Plain text: https://secwatch.observer/filing/0001104659-26-033867.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported full year 2026 results: revenue Expects 2026 revenue of $30-32 million. Guidance initiated.
  - Period: full year 2026
  - Revenue: Expects 2026 revenue of $30-32 million
  - Guidance: initiated
  - Result: guidance update
  source text: Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm
- Earnings Releases
  MAXCYTE, INC. reported fourth quarter ended December 31, 2025 results: revenue total revenue of $7.3 million, net income net loss was $9.6 million.
  - Period: fourth quarter ended December 31, 2025
  - Revenue: total revenue of $7.3 million
  - Net income: net loss was $9.6 million
  - Result: reported results
  source text: Total revenue for the fourth quarter of 2025 was $7.3 million, compared to $8.7 million in the fourth quarter of 2024, representing a decrease of 16%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.